Logo

Microarray-based NIPT Firm CellScape Shuts Down

Nov 08, 2014 | staff reporter

NEW YORK (GenomeWeb) – Microarray-based non-invasive prenatal testing firm CellScape has shut down.

According to its LinkedIn page, the company, which had been headquartered in Newark, Calif., ceased operations in September.

CellScape was founded in 2008 and was developing an NIPT using chromosomal microarrays for detecting fetal aneuploidies, as well as genetic disorders that generally have required invasive methods. In 2013, company officials told GenomeWeb Daily News that the firm planned to launch its test called Clarity in the second half of this year. That target date was later pushed back to 2015.

According to its LinkedIn page, CellScape had between 11 and 50 employees. Its founders were Karen Drexler, Bhairavi Parikh, and James Stone.

Filed under

Microarrays & Multiplexing
Diagnostics
Disease Research
aneuploidy
microarrays
chromosomal microarray
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.